Island Pharmaceuticals Announces Purchase Of Galidesivir Antiviral Program From Biocryst Pharmaceuticals
July 9 (Reuters) - Island Pharmaceuticals Ltd ILA.AX:
ACQUISITION OF GALIDESIVIR ANTIVIRAL PROGRAM FROM BIOCRYST PHARMACEUTICALS
DEAL COMPLETED FOR BASE PURCHASE PRICE OF $550,000
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.